Left Main Disease at an Intermediate Score: PCI or Bypass
A single patient whose SYNTAX score sits precisely where two major trials asked the same question and reached different answers. The disagreement isn't settled by more data — it's handed, deliberately, back to the patient himself.
J.O., a 68-year-old man, has lived alone since his wife died two years ago, and still does his next-door neighbor's taxes every spring out of habit more than any real need to keep working. He has had hyperlipidemia for over a decade, well controlled on a statin, and blood pressure that runs a little high but has never quite crossed into a number anyone treated. Over the past month, the walk to his mailbox has started producing a tightness across his chest that eases within a few minutes of stopping — nothing dramatic, nothing that sent him to an emergency department, just persistent enough that his daughter finally got him to see a cardiologist.
A stress test was unambiguously positive, and angiography found unprotected left main coronary artery disease with an intermediate SYNTAX score, calculated at 27 — intermediate spans 23 to 32 — high enough to rule out medical therapy alone as a real option, low enough that it sits squarely in the zone where percutaneous and surgical revascularization have gone head to head in trials that didn't agree with each other. EXCEL found no significant difference in the composite of death, stroke, and myocardial infarction between PCI and CABG at three years, though longer follow-up raised a mortality signal that favored surgery; NOBLE found CABG superior to PCI on the same kind of composite, driven mainly by more myocardial infarction and repeat revascularization in the stenting arm. Two trials asking almost the same question reached different answers, and his SYNTAX score sits exactly where that disagreement lives.
Two trials, one intermediate score
EXCEL is the larger and more contemporary of the two trials, and at three years it showed no significant difference in the composite outcome. He's 68, lives independently, still drives himself everywhere, and has told me plainly he'd rather avoid a sternotomy and the recovery that comes with it if the data genuinely support an equivalent option. PCI with a current-generation drug-eluting stent is that option.
EXCEL's own longer-term follow-up is the part that concerns me — the all-cause mortality difference that emerged after three years trended toward surgery, and NOBLE found CABG outright superior on its composite endpoint, largely from more repeat revascularization and MI in the PCI arm. He has a reasonable life expectancy ahead of him, which is exactly the scenario where a more durable revascularization strategy has more years to pay that durability back.
Recovery from surgery is a real cost, and I'm not minimizing it — but "wanting to avoid it" is a preference about the next two months, and the trial disagreement we're discussing is about the next five to ten years. Both deserve weight; neither should silently substitute for the other.
Whichever way this goes, the medication burden afterward is different enough that it belongs in the same conversation as the procedure itself, especially for a man managing his own regimen alone. PCI means dual antiplatelet therapy for six months as the guideline default for stable disease — aspirin plus clopidogrel, not one of the potent agents, which are established for acute coronary syndromes rather than for chronic coronary syndrome and would mainly add bleeding here. Left main anatomy is complex enough that some operators would still argue for a potent agent or a longer course, but that is a deviation from the default, not the default itself — and either way it carries real bleeding risk and real consequences if a dose gets missed. CABG means aspirin and a statin long-term, a simpler regimen, at the cost of the surgery and recovery already on the table. That's not a tiebreaker by itself, but for a patient managing his own pill bottles at home, it's not nothing either.
Medical therapy started immediately regardless of the eventual choice: aspirin, high-intensity atorvastatin, and metoprolol. Neither specialist claimed the other trial was wrong; both acknowledged the field itself hasn't resolved this at an intermediate SYNTAX score.
PCI with a current-generation stent, accepting six months of dual antiplatelet therapy managed on his own.
CABG, accepting the surgical recovery for the mortality signal favoring surgery at longer follow-up.
The actual choice was left to a documented conversation between J.O. and both specialists, held once his daughter could be present.